Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women

Circulation

Volumn 106, Issue 15, 2002, Pages 1930-1937

  Blake, Gavin J ^a   Otvos, James D ^a   Rifai, Nader ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Lipoproteins; Risk factors

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ROC CURVE; STROKE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MIDDLE AGED; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0037044396     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000033222.75187.B9     Document Type: Article

References (27)

1. Otvos JD, Jeyarajah EJ, Bennett DW. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem. 1991;37:377-386.
2. Otvos JD, Jeyarajah EJ, Bennett DW, et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992;38:1632-1638.
3. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180.
4. Freedman DS, Otvos JD, Jeyarajah EJ, et al. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:1046-1053.
5. Ridker PM. High-sensitivity C-reactive protein (hs-CRP): a potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
6. Buring JE, Hennekens CH. The Women's Health Study: summary of the study design. J Myocardial Ischemia. 1992;4:27-29.
7. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136-2141.
8. Redgrave TG, Carlson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res. 1979;20:217-229.
9. Grundy SM, Vega GL, Otvos JD, et al. Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. J Lipid Res. 1999;40:229-234.
10. Rainwater DL, Moore PH Jr, Shelledy WR, et al. Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res. 1997;38:1261-1266.
11. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
12. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002;90:89-94.
13. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
14. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
15. Kamigaki AS, Siscovick DS, Schwartz SM, et al. Low density lipoprotein particle size and risk of early-onset myocardial infarction in women. Am J Epidemiol. 2001;153:939-945.
16. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996;276:882-888.
17. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001;286:1468-1474.
18. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation. 2001;104:2295-2299.
19. Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
20. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 1994;343:75-79.
21. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273-278.
22. McNamara JR, Small DM, Li Z, et al. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res. 1996;37:1924-1935.
23. Tallis GA, Shephard MDS, Sobecki S, et al. The total apolipoprotein B/LDL-cholesterol ratio does not predict LDL particle size. Clin Chim Acta. 1995;240:63-73.
24. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104:159-171.
25. Miller M, Dolinar C, Cromwell W, et al. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol. 2001;87:232-234, A9.
26. Tangney CC, Mosca LJ, Otvos JD, et al. Oral 17β-estradiol and medroxyprogesterone acetate therapy in postmenopausal women increases HDL particle size. Atherosclerosis. 2001;155:425-430.
27. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270-274.